Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JOENJA vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Differentiated thyroid cancer (DTC) refractory to radioactive iodine,Renal cell carcinoma (RCC) in combination with everolimus,Hepatocellular carcinoma (HCC) first-line treatment in combination with pembrolizumab
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For Cr Cl 30-60 m L/min: 2.5 mg orally once daily; for Cr Cl <30 m L/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Safety and efficacy not established in pediatric patients under 18 years.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment; monitor renal function and adjust dose based on Cr Cl.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
None.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypertension (including hypertensive crisis),Cardiac dysfunction (reduced LVEF),Arterial thromboembolic events,Hepatic impairment (including hepatotoxicity),Renal impairment (including proteinuria),Hemorrhage,Gastrointestinal perforation or fistula,QT prolongation,Reversible posterior leukoencephalopathy syndrome (RPLS),Thyroid dysfunction,Wound healing complications
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
None known
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Due to increased plasma volume and renal clearance during pregnancy, higher doses may be required. Consider dose titration based on therapeutic drug monitoring and clinical response. No specific dose adjustment is established; individualize therapy.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably.,Do not crush, chew, or split tablets; swallow whole.,If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose.,Avoid grapefruit, grapefruit juice, and star fruit during treatment.,Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose.,Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JOENJA vs ALFENTA, answered by our medical review team.
JOENJA is a Sphingosine 1-Phosphate Receptor Modulator that works by JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JOENJA and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JOENJA is: JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JOENJA and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JOENJA is classified as Category C. First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.